TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06663332: CNTO1959ISD3001: A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study to Evaluate the Safety of Guselkumab in Pediatric Participants With Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthri

Sponsor: Janssen Research & Development, LLC · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 196 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$587,880

Rescue Site Savings

+$391,920

Unlock Full NCT06663332 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06663332 Rescue Dossier →